Astec LifeSciences Limited (ASTEC)
Press Release
Press Release - Q1FY27
- Consolidated total income ₹84.3 crore, down 8.0% y-y from ₹91.6 crore
- Consolidated EBITDA ₹0.1 crore, improved from loss of ₹10.5 crore y-y
- Loss after tax ₹18.7 crore, improved from loss of ₹33.0 crore y-y
- Enterprise Products revenue up 42% to ₹51.8 crore driven by volume and realizations
- CDMO Products revenue down 42% to ₹31.8 crore due to high base last year
- Exports declined 27.5% to ₹33.3 crore; domestic revenue up 11.3% to ₹50.3 crore
- Chairperson: demand-supply imbalance expected to even out medium term; focus on new products and operational efficiencies
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ASTEC — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ASTEC to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Astec LifeSciences Limited
Important.
The summary above is generated automatically from Astec LifeSciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.